[HTML][HTML] An infectious SARS-CoV-2 B. 1.1. 529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
The emergence of the highly transmissible B. 1.1. 529 Omicron variant of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …
The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2
AL Cathcart, C Havenar-Daughton, FA Lempp, D Ma… - biorxiv, 2021 - biorxiv.org
ABSTRACT VIR-7831 and VIR-7832 are dual action monoclonal antibodies (mAbs)
targeting the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS …
targeting the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS …
[HTML][HTML] Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA. 2.75
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant
BA. 2.75 emerged recently and appears to be spreading. It has nine mutations in spike …
BA. 2.75 emerged recently and appears to be spreading. It has nine mutations in spike …
Neutralization of SARS-CoV-2 Omicron BA. 2 by therapeutic monoclonal antibodies
H Zhou, T Tada, BM Dcosta, NR Landau - Biorxiv, 2022 - ncbi.nlm.nih.gov
Monoclonal antibody therapy for the treatment of SARS-CoV-2 infection has been highly
successful in decreasing disease severity; however, the recent emergence of the heavily …
successful in decreasing disease severity; however, the recent emergence of the heavily …
[HTML][HTML] Antibody evasion properties of SARS-CoV-2 Omicron sublineages
The identification of the Omicron (B. 1.1. 529.1 or BA. 1) variant of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in Botswana in November 2021 1 immediately …
syndrome coronavirus 2 (SARS-CoV-2) in Botswana in November 2021 1 immediately …
Convalescent-phase sera and vaccine-elicited antibodies largely maintain neutralizing titer against global SARS-CoV-2 variant spikes
The increasing prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) variants with spike protein mutations raises concerns that antibodies elicited by natural …
2) variants with spike protein mutations raises concerns that antibodies elicited by natural …
[HTML][HTML] Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …
[HTML][HTML] SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic infecting more than 106 million people and causing 2.3 million deaths …
COVID-19 pandemic infecting more than 106 million people and causing 2.3 million deaths …
[HTML][HTML] Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …
[HTML][HTML] Infection-and vaccine-induced antibody binding and neutralization of the B. 1.351 SARS-CoV-2 variant
VV Edara, C Norwood, K Floyd, L Lai… - Cell host & …, 2021 - cell.com
The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising
concerns about the efficacy of infection-or vaccine-induced antibodies. We compared …
concerns about the efficacy of infection-or vaccine-induced antibodies. We compared …